Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Restarting Anticoagulation After Traumatic Intracranial Hemorrhage (Restart tICrH): a Prospective Randomized Open Label Blinded Endpoint (PROBE) Pragmatic Time-dose, Response Adaptive Clinical Trial

NCT04229758 is registered in ClinicalTrials.gov with University of Texas at Austin as lead sponsor.

NCT NCT04229758
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04229758 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Restarting Anticoagulation After Traumatic Intracranial Hemorrhage (Restart tICrH): a Prospective Randomized Open Label Blinded Endpoint (PROBE) Pragmatic Time-dose, Response Adaptive Clinical Trial
Lead sponsor
University of Texas at Austin
Phase
Phase 3
Overall status
Not yet recruiting
Start date
October 31, 2021
Completion date
February 28, 2027
Enrollment
1,100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bleeding, hemorrhage, intracranial hemorrhages, trauma